Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Am J Transplant. 2016 Jul 7;16(11):3121–3130. doi: 10.1111/ajt.13865

Figure 2. Donor specific antibody in conjunction with adoptively transferred NK cells induces chronic allograft vasculopathy.

Figure 2

Administration of DSA (α-H2k IgG2a) into B6.rag−/− recipients bearing C3H allografts induced CAV. This effect could be duplicated in B6.rag−/−γc−/− (those lacking NK cells) by adoptive transfer of B6 wild-type NK cells (p > 0.999). In contrast, B6.rag−/−γc−/− recipients that received either no treatment or DSA alone, as well as B6.rag−/− recipients that received no treatment showed no significant CAV formation. The p values between groups were calculated with the Mann-Whitney U test; the numbers in parentheses indicate the number of allografts examined. (* p ≤ 0.05. ** p ≤ 0.01, *** p ≤ 0.001, and **** p ≤ 0.0001). CAV, chronic allograft vasculopathy; DSA, donor-specific antibody.